{"doi":"10.1016/j.jlr.2023.100377","title":"Bioactive lipid mediators in plasma are predictors of preeclampsia irrespective of aspirin therapy","abstract":"There are few early biomarkers to identify pregnancies at risk of preeclampsia (PE) and abnormal placental function. In this cross-sectional study, we utilized targeted ultra-performance liquid chromatography-ESI MS/MS and a linear regression model to identify specific bioactive lipids that serve as early predictors of PE. Plasma samples were collected from 57 pregnant women prior to 24-weeks of gestation with outcomes of either PE (n = 26) or uncomplicated term pregnancies (n = 31), and the profiles of eicosanoids and sphingolipids were evaluated. Significant differences were revealed in the eicosanoid, (±)11,12 DHET, as well as multiple classes of sphingolipids; ceramides, ceramide-1-phosphate, sphingomyelin, and monohexosylceramides; all of which were associated with the subsequent development of PE regardless of aspirin therapy. Profiles of these bioactive lipids were found to vary based on self-designated race. Additional analyses demonstrated that PE patients can be stratified based on the lipid profile as to PE with a preterm birth linked to significant differences in the levels of 12-HETE, 15-HETE, and resolvin D1. Furthermore, subjects referred to a high-risk OB/GYN clinic had higher levels of 20-HETE, arachidonic acid, and Resolvin D1 versus subjects recruited from a routine, general OB/GYN clinic. Overall, this study shows that quantitative changes in plasma bioactive lipids detected by ultra-performance liquid chromatography-ESI-MS/MS can serve as an early predictor of PE and stratify pregnant people for PE type and risk.","journal":"Journal of Lipid Research","year":2023,"id":336187,"datarank":0.4493598410330987,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.0,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9562,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":862338,"name":"H. Patrick MacKnight","orcid":"0000-0003-3232-6155","position":1,"is_corresponding":false},{"id":1066611,"name":"L. Alexis Hoeferlin","orcid":"0000-0001-7569-8712","position":2,"is_corresponding":false},{"id":1067098,"name":"Sonya L. Washington","orcid":null,"position":3,"is_corresponding":false},{"id":383663,"name":"Chelsea Sawyers","orcid":"0000-0001-9704-6555","position":4,"is_corresponding":false},{"id":390556,"name":"Kellie J. Archer","orcid":"0000-0003-1555-5781","position":5,"is_corresponding":false},{"id":187499,"name":"Jerome F. Strauss","orcid":null,"position":6,"is_corresponding":false},{"id":493778,"name":"Scott W. Walsh","orcid":"0000-0001-8234-025X","position":7,"is_corresponding":false},{"id":489008,"name":"Charles E. Chalfant","orcid":"0000-0002-5844-5235","position":8,"is_corresponding":false},{"id":489004,"name":"Daniel Stephenson","orcid":"0000-0002-5698-3400","position":0,"is_corresponding":true}],"reference_count":99,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:10:17.243221Z","pmid":"37119922","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}